Investigational drug · Phase 3
TTAX01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 1, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "TTAX01"
First trial start
2020
Nov 20, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TTAX01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Foot Infection
- Non-healing Wound
- Non-healing Diabetic Foot Ulcer
Approved drugs for the same conditions: Cardiovascular and metabolic · Infectious disease and vaccines · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "TTAX01" as an intervention, largest first.
- Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)Pivotal-lookingCompleted
BioTissue Holdings, IncIndustry
NCT04176120 · 220 participants · Start Jul 1, 2020 · Primary completion Jan 25, 2024
Drug: TTAX01 · For: Diabetic Foot Infection; Non-healing Wound; Non-healing Diabetic Foot Ulcer
Sites: San Francisco, California; Sylmar, California; Miami, Florida · 16 sites in all
- Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)Pivotal-lookingCompleted
BioTissue Holdings, IncIndustry
NCT04450693 · 106 participants · Start Nov 20, 2020 · Primary completion Mar 24, 2025
Drug: TTAX01 · For: Diabetic Foot Infection; Non-healing Wound; Non-healing Diabetic Foot Ulcer
Sites: Guntersville, Alabama; Tucson, Arizona; Los Angeles, California · 16 sites in all
BioTissue Holdings, IncIndustry
NCT03230175 · 32 participants · Start Oct 4, 2017 · Primary completion Jan 10, 2019
Drug: TTAX01; Systemic antibiotics · For: Non-healing Wound; Non-healing Diabetic Foot Ulcer; Diabetic Foot Infection
Sites: Phoenix, Arizona; Sylmar, California; Miami, Florida · 11 sites in all
BioTissue Holdings, IncIndustry
NCT03818828 · 31 participants · Start Feb 14, 2019 · Primary completion Dec 20, 2019
Drug: TTAX01 · For: Venous Leg Ulcer
Sites: Carlsbad, California; Sylmar, California; North Chicago, Illinois · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.